1,3-Thiazolidine-4-Ones: Copper Nickel Oxide Bimetallic Nanoparticle Catalysed Synthesis, Anticancer Potential and Molecular Modeling Studies

Cancer is a leading cause of death worldwide. Inhibiting mitosis is the most effective clinical technique for cancer treatment. In this investigation, copper-nickel oxide nanoparticles synthesized by electrochemical synthesis and analysed by UV-visible spectrophotometer (UV 1800 Shimadzu), a Fourier transform infrared spectrophotometer (FTIR Affinity 1 Shimadzu), a thermogravimetric analyser (TGA 50 Thermoanalyzer Shimadzu), a high-end X-ray diffractometer, scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS), and transmission electron microscopy elected area electron diffraction (TEM-SAED) techniques. The calcinated copper nickel oxide nanoparticles were used successfully as a catalyst to synthesis of 2-(2-substituted-4-oxothiazolidin-3-yl)-1,9-dihydro-purin-6-ones. The title compounds were characterized by melting point, IR, 1H NMR, 13C NMR and LC-HRMS/MS spectroscopy. Using Sulforhodamine B (SRB) test, all newly synthesized compounds were evaluated in vitro for anti-cancer, anti-inflammatory, antioxidant, and angiogenesis activities. The compounds GB-6, GB-8, GB-10 exhibited significant in vitro anti-inflammatory activityin the range of IC50:179.65-194.59 μg/ml as compared with aceclofenac (IC50: 191.19 μg/mL) and the antioxidant activity by DPPH radical scavenging assay the compounds GB-6 (IC50: 11.96 μg/mL), GB-8 (IC50:10.67 μg/mL) and GB-10 (IC50: 9.08 μg/mL) exhibited excellent radical scavenging activities compared to ascorbic acid (IC50:13.04 μg/mL) and by the KMnO4 radical scavenging assay the compounds GB-2 (IC50: 15.33 μg/mL), GB-4 (IC50: 23.60 μg/mL), GB-8 (IC50: 24.93 μg/mL), GB-10 (IC50: 24.96 μg/mL) exhibited good radical scavenging activities compared to ascorbic acid (IC50: 26.55 μg/mL). Further development of anticancer drugs may be enabled by the discovery of related compounds to the anticancer agent, such as compound (GB-6), compound (GB-8), and compound (GB-10) as polo-like kinase 1 inhibitors.